A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TriSalus Life Sciences's Debt-to-Equity or its related term are showing as below:
TLSI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.73 Med: -0.91 Max: 2.69
Current: 2.69
During the past 5 years, the highest Debt-to-Equity Ratio of TriSalus Life Sciences was 2.69. The lowest was -1.73. And the median was -0.91.
TLSI's Debt-to-Equity is ranked worse than 95.89% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.225
vs TLSI: 2.69
TriSalus Life Sciences (NAS:TLSI) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
TriSalus Life Sciences Debt-to-Equity Related Terms
TriSalus Life Sciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for TriSalus Life Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLSI vs TMCI, LAB, SENS: Debt-to-Equity Comparison
For the Medical Devices subindustry, TriSalus Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TriSalus Life Sciences Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TriSalus Life Sciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TriSalus Life Sciences (TLSI) has a Debt-to-Equity of 2.69 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TriSalus Life Sciences and its competitors. According to the industry distribution chart, TriSalus Life Sciences ranks #677 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 95.9%.
Is TriSalus Life Sciences' Debt-to-Equity too high?
TriSalus Life Sciences' current Debt-to-Equity is 2.69. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. TriSalus Life Sciences' value of 2.69 is 1095.6% above this industry median. Based on the distribution chart, TriSalus Life Sciences ranks #677 out of 706 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Debt-to-Equity compare to TMCI and LAB?
According to the Medical Devices & Instruments industry distribution chart, TriSalus Life Sciences ranks #677 out of 706 companies for Debt-to-Equity. This places TriSalus Life Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.23. TriSalus Life Sciences' value of 2.69 is 1095.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TriSalus Life Sciences's current Debt-to-Equity of 2.69 is 1095.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on TriSalus Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TriSalus Life Sciences's current Debt-to-Equity is 2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Fairly Valued. The stock's GF Value™ is $4.31, compared to a current price of $4.14 — trading 3.9% below its estimated fair value. The current Debt-to-Equity is 2.69 and 1095.6% above the Medical Devices & Instruments industry median of 0.23. TriSalus Life Sciences' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Debt-to-Equity is 2.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TriSalus Life Sciences (TLSI) Overvalued in 2026?
Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued.
The current stock price of $4.14 is trading 3.9% below its estimated GF Value™ of $4.31.
GuruFocus considers TriSalus Life Sciences to be Fairly Valued.
Key valuation signals for TLSI:
Debt-to-Equity: 2.69
GF Value™: $4.31 vs. price of $4.14 (3.9% below fair value)
Industry Position: 1095.6% above the Medical Devices & Instruments median (#677 of 706)
No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score
Get the complete analysis for TLSI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLSI has been successfully added to your 
